La Jolla Institute for Immunology (LJI), one of the leading research organisations dedicated to studying the immune system recently announced that it has signed a licensing agreement with Leinco Technologies, Inc., a developer and manufacturer of leading-edge recombinant proteins, antibodies, and conjugates. Leinco also provides custom manufacturing services to the diagnostic and biopharmaceutical industries to leverage proprietary COVID-19 antibodies developed at LJI.
0 comments
Hide comments